Foundation Medicine’s Founding Advisors are world leaders in the fields of cancer genomics, cancer biology, clinical oncology, and information sciences. They are instrumental in guiding the Foundation Medicine Management Team with the expertise required to bring cancer genomics into the routine practice of medicine.
- Eric Lander, Ph.D., Broad Institute, Harvard Medical School, Massachusetts Institute of Technology
- Todd Golub, M.D., Broad Institute, Dana-Farber Cancer Institute, Harvard Medical School
- Levi Garraway, M.D., Ph.D., Dana-Farber Cancer Institute, Harvard Medical School, Broad Institute
- Matthew Meyerson, M.D., Ph.D., Dana-Farber Cancer Institute, Harvard Medical School, Broad Institute
Eric Lander, Ph.D. Broad Institute, Harvard Medical School, Massachusetts Institute of Technology
Eric Lander is one of the driving forces behind today's revolution in genomics and serves as the Founding Director of the Broad Institute, Professor of Biology at Massachusetts Institute of Technology and Professor of Systems biology at Harvard Medical School. He is an innovator in genome technology and was a key leader of the Human Genome Project.
Today, Dr. Lander is using the knowledge of the human genome to tackle the fundamental issue of medicine: to find the causes versus the symptoms of disease. Dr. Lander has also been a successful entrepreneur and was Co-founder of Millennium Pharmaceuticals and Infinity Pharmaceuticals.
Lander received his Ph.D. in mathematics from Oxford in 1981 as a Rhodes Scholar. He joined Whitehead Institute in 1986 and founded the Whitehead Institute/Massachusetts Institute of Technology Center for Genome Research in 1990. He taught managerial economics on the faculty of the Harvard Business School from 1981-1989.
Todd Golub, M.D. Broad Institute, Dana-Farber Cancer Institute, Harvard Medical School
Todd Golub, a world leader in applying genomic tools to the classification and study of cancers, is a founding member of the Broad Institute and serves as Director of its Cancer Program. His work focuses on using the human genome to understand the biological and clinical challenges facing cancer medicine. He has made fundamental discoveries in the molecular basis of childhood leukemia, and pioneered the use of genomic approaches, particularly DNA microarrays, to cancer biology.
In 1997, Dr. Golub joined the Whitehead Institute/Massachusetts Institute of Technology Center of Genome Research, now part of the Broad Institute, as Director of its program in cancer research. Dr. Golub also serves as Chief Scientific Officer of the Broad Institute. He is the Charles A. Dana Investigator in Human Cancer Genetics at the Dana-Farber Cancer Institute, an investigator at Howard Hughes Medical Institute and professor of pediatrics at Harvard Medical School.
Dr. Golub is the recipient of multiple awards, including the 2009 AACR Richard and Hinda Rosenthal Memorial Award, the 2008 E. Mead Johnson Award from the Society for Pediatric Research, the 2007 Oski Prize of the American Society of Pediatric Hematology-Oncology, Discover Magazine's Inventor of the Year (Health Category), the Daland Prize of the American Philosophical Society, the Outstanding Achievement Award for the American Association for Cancer Research and the 2007 Paul Marks Prize for Cancer Research. Dr. Golub also serves as Chairman of the Board of Scientific Advisors of the National Cancer Institute. Dr. Golub received his B.A. in 1985 from Carleton College and his M.D. in 1989 from the University of Chicago Pritzker School of Medicine.
Levi Garraway, M.D., Ph.D. Dana-Farber Cancer Institute, Harvard Medical School, Broad Institute
Dr. Levi Garraway is an Associate Professor of Medicine in the Department of Medical Oncology at the Dana-Farber Cancer Institute, Harvard Medical School. Dr. Garraway is also a faculty member of Dana-Farber’s Center for Cancer Genome Discovery and a Senior Associate Member of the Broad Institute, where he leads several large cancer genome analyses and functional genomics efforts in the Broad Cancer Program.
Dr. Garraway leads a 16-member investigative team in cancer genomics at Dana-Farber and the Broad Institute. His research has informed several gene targets and “druggable” pathways relevant to the genesis and therapeutic vulnerabilities of melanoma and other malignancies. Dr. Garraway’s group developed OncoMap, a platform for systematic cancer mutation profiling that has inspired multiple personalized cancer medicine efforts across the U.S. and beyond.
Dr. Garraway has been the recipient of several awards and honors, including the Minority Scholar Award from the American Association of Cancer Research, the Partners in Excellence Award from the Massachusetts General Hospital, and the Career Award in the Biomedical Sciences from the Burroughs-Wellcome Fund. In the fall of 2007, Dr. Garraway was awarded one of the first prestigious New Innovator Awards from the National Institutes of Health, worth $1.5 million over five years. The Innovator Awards were given to the top 29 scientists from over 2200 applicants nationwide. In 2009, Dr. Garraway was inducted into the American Society for Clinical Investigation.
Matthew Meyerson, M.D., Ph.D. Dana-Farber Cancer Institute, Harvard Medical School, Broad Institute
Matthew Meyerson is a leader in the field of cancer genomics with a focus on lung cancer. He serves as Professor of Pathology at Dana-Farber Cancer Institute and Harvard Medical School, and a Senior Associate Member of the Broad Institute.
Together with Drs. Bill Sellers, Bruce Johnson and Pasi Janne, the Meyerson group identified somatic mutations in the epidermal growth factor gene, EGFR, in lung adenocarcinomas, that predict response to the EGFR kinase inhibitors, gefitinib and erlotinib. The Meyerson group and collaborators have also discovered other activated kinase genes in cancer, including JAK2 in polycythemia vera, FGFR2 in endometrial cancer, ALK in neuroblastoma, and DDR2 and FGFR1 in squamous cell lung cancer.
The laboratory has pioneered technical and computational approaches for cancer genome research, including methods for copy number determination with single nucleotide polymorphism (SNP) arrays, leading to identification of oncogenes including NKX2-1, SOX2, and MCL1. In addition, the Meyerson group performed the first next-generation sequencing analysis of cancer DNA and developed the computational subtraction approach to discovery of novel disease-causing microbes.
Dr. Meyerson plays a leading role in “The Cancer Genome Atlas” (TCGA), as principal investigator of the Genome Characterization Center at the Broad Institute, focused on copy number and structural alterations. He co-chairs the lung cancer working group with Drs. Steve Baylin and Ramaswamy Govindan. Dr. Meyerson and Dr. Bill Hahn direct the Center for Cancer Genome Discovery at Dana-Farber Cancer Institute.
Dr. Meyerson received his M.D. from Harvard Medical School and his Ph.D. from Harvard University. He served as a resident in Clinical Pathology at Massachusetts General Hospital and a post-doctoral fellow at the Whitehead Institute with Dr. Robert Weinberg. Among other prizes, Dr. Meyerson has been awarded the Paul Marks Prize in Cancer Research from Memorial Sloan-Kettering Cancer Center and the Team Science Award from the American Association for Cancer Research.